Acute-phase Serum Amyloid A Regulates Tumor Necrosis Factor α and Matrix Turnover and Predicts Disease Progression in Patients with Inflammatory Arthritis Before and After Biologic Therapy
Overview
Authors
Affiliations
Objective: To investigate the relationship between acute-phase serum amyloid A (A-SAA) and joint destruction in inflammatory arthritis.
Methods: Serum A-SAA and C-reactive protein (CRP) levels, the erythrocyte sedimentation rate (ESR), and levels of matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, MMP-13, tissue inhibitor of metalloproteinases 1 (TIMP-1), vascular endothelial growth factor (VEGF), and type I and type II collagen-generated biomarkers C2C and C1,2C were measured at 0-3 months in patients with inflammatory arthritis commencing anti-tumor necrosis factor α (anti-TNFα) therapy and were correlated with 1-year radiographic progression. The effects of A-SAA on MMP/TIMP expression on RA fibroblast-like synoviocytes (FLS), primary human chondrocytes, and RA/psoriatic arthritis synovial explant cultures were assessed using real-time polymerase chain reaction, enzyme-linked immunosorbent assay, antibody protein arrays, and gelatin zymography.
Results: Serum A-SAA levels were significantly (P < 0.05) correlated with MMP-3, the MMP-3:TIMP-1 ratio, C1,2C, C2C, and VEGF. The baseline A-SAA level but not the ESR or the CRP level correlated with the 28-joint swollen joint count and was independently associated with 1-year radiographic progression (P = 0.038). A-SAA increased MMP-1, MMP-3, MMP-13, and MMP/TIMP expression in RA FLS and synovial explants (P < 0.05). In chondrocytes, A-SAA induced MMP-1, MMP-3, and MMP-13 messenger RNA and protein expression (all P < 0.01), resulting in a significant shift in MMP:TIMP ratios (P < 0.05). Gelatin zymography revealed that A-SAA induced MMP-2 and MMP-9 activity. Blockade of the A-SAA receptor SR-B1 (A-SAA receptor scavenger receptor-class B type 1) inhibited MMP-3, MMP-2, and MMP-9 expression in synovial explant cultures ex vivo. Importantly, we demonstrated that A-SAA has the ability to induce TNFα expression in RA synovial explant cultures (P < 0.05).
Conclusion: A-SAA may be involved in joint destruction though MMP induction and collagen cleavage in vivo. The ability of A-SAA to regulate TNFα suggests that A-SAA signaling pathways may provide new therapeutic strategies for the treatment of inflammatory arthritis.
Van Damme J, Struyf S, Proost P, Opdenakker G, Gouwy M Int J Mol Sci. 2025; 26(5).
PMID: 40076881 PMC: 11900440. DOI: 10.3390/ijms26052258.
Coleman L, Byrne J, Edwards S, OHara R J Pers Med. 2025; 15(1).
PMID: 39852209 PMC: 11766770. DOI: 10.3390/jpm15010017.
AA Amyloidosis: A Contemporary View.
Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas S Curr Rheumatol Rep. 2024; 26(7):248-259.
PMID: 38568326 PMC: 11219434. DOI: 10.1007/s11926-024-01147-8.
den Hartigh L, May K, Zhang X, Chait A, Blaser M Front Cardiovasc Med. 2023; 10:1197432.
PMID: 37396595 PMC: 10311072. DOI: 10.3389/fcvm.2023.1197432.
Xu Z, Wu Y, Fu G, Chen X, Sun J, Tian J Int J Mol Sci. 2023; 24(8).
PMID: 37108666 PMC: 10138873. DOI: 10.3390/ijms24087505.